Immunome Inc (IMNM)

Currency in USD
22.32
+0.12(+0.54%)
Closed·
21.89-0.43(-1.93%)
·
Advertisement
IMNM is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
21.5922.91
52 wk Range
8.6627.65
Key Statistics
Prev. Close
22.2
Open
21.73
Day's Range
21.59-22.91
52 wk Range
8.66-27.65
Volume
688.49K
Average Volume (3m)
1.35M
1-Year Change
110.9641%
Book Value / Share
5.2
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IMNM Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
35.77
Upside
+60.26%
Members' Sentiments
Bearish
Bullish
ProTips
10 analysts have revised their earnings upwards for the upcoming period

Immunome Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Analyst Ratings

14 Buy
0 Hold
0 Sell
Ratings:
14 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 35.77
(+60.26% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy40.00+79.21%-Maintain09/07/2026
Truist Securities
Buy37.00+65.77%36.00Maintain28/05/2026
Barclays
Buy36.00+61.29%-New Coverage28/05/2026
Lake Street
Buy30.00+34.41%32.00Maintain05/03/2026
Craig-Hallum
Buy36.00+61.29%33.00Maintain04/03/2026

Earnings

Latest Release
12/05/2026
EPS / Forecast
-0.48 / -0.55
Revenue / Forecast
-- / 200K
EPS Revisions
Last 90 days

Compare IMNM to Peers and Sector

Metrics to compare
IMNM
Peers
Sector
Relationship
P/E Ratio
−11.3x−6.1x−0.4x
PEG Ratio
−0.45−0.460.00
Price/Book
4.3x2.1x2.6x
Price / LTM Sales
629.6x24.9x3.0x
Upside (Analyst Target)
62.2%62.4%50.8%
Fair Value Upside
Unlock−17.7%9.4%Unlock

Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
58.67M51.80%1.34B
Other Institutional Investors
80.73M48.20%1.85B
Public Companies & Retail Investors
0.000.00%0.00
Total
139.4M100.00%3.2B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
T. Rowe Price Group, Inc.16.97%19,222,874440,588
FMR LLC14.98%16,969,954388,951

People Also Watch

16.360
TH
-3.02%
42.640
KOD
+3.37%
15.050
QTTB
-1.05%
9.690
OMER
+5.10%
26.56
DAN
-0.93%

FAQ

What Is the Immunome (NASDAQ: IMNM) Share Price Today?

The Immunome stock price today is 22.32 USD.

What Stock Exchange Does Immunome (IMNM) Trade On?

Immunome is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Immunome?

The stock symbol (also called a 'ticker') for Immunome is "IMNM."

What Is the Current Immunome Market Capitalisation?

As of today, Immunome (NASDAQ: IMNM) market cap is 2.53B USD.

What Is Immunome's (IMNM) Earnings Per Share (TTM)?

The Immunome EPS is currently -2.34 (Trailing Twelve Months).

When Is the Next Immunome Earnings Date?

Immunome's next earnings report will be released on 19/08/2026.

Is IMNM a Buy or Sell From a Technical Analyst Perspective?

Based on today's Immunome moving averages and other technical indicators, the daily buy/sell signal for IMNM stock is Buy.

How Many Times Has Immunome Stock Split?

Immunome has split 0 times. (See the IMNM stock split history page for full effective split date and price information.)

How Many Employees Does Immunome Have?

Immunome has 206 employees, based on their latest Companies House report.

What is the current trading status of Immunome (NASDAQ: IMNM)?

As of 18/07/2026, Immunome (IMNM) is trading at a share price of 22.32 USD, with a previous close of 22.20 USD. The stock has fluctuated within a day range of 21.59 USD to 22.91 USD, while its 52-week range spans from 8.66 USD to 27.65 USD.

What Is Immunome (IMNM) Price Target According to Analysts?

The average 12-month price target for Immunome is 35.77 USD, with a high estimate of 40 USD and a low estimate of 30 USD. 14 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +60.26% Upside potential.

What Is the IMNM Premarket Price?

IMNM's last pre-market stock price is 21.80 USD. The pre-market share volume is 250.00, and the stock has decreased by -0.40, or -1.80%.

What Is the IMNM After Hours Price?

IMNM's last after hours stock price is 21.89 USD, the stock has decreased by -0.43, or -1.93%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.